DBV Technologies refreshes ATM program with $150M ADS offering

DBV Technologies (Euronext: DBV, NASDAQ: DBVT), a biopharmaceutical company, has filed a shelf registration statement on Form S-3ASR with the U.S. Securities and Exchange Commission to refresh its at-the-market offering program, allowing sales of up to $150 million in American Depositary Shares.

The ATM program was established under a sales agreement dated September 5, 2025, with Citizens JMP Securities, LLC acting as sales agent. Each ADS represents five ordinary shares of the company. The refreshed program carries forward previously registered but unsold ADSs along with newly registered capacity, bringing the total available for issuance and sale to $150 million. The terms and conditions of the program remain unchanged.

The company stated it intends to use net proceeds primarily for manufacturing expansion, biologics license applications covering ages 1 through 7, launch preparation for Viaskin Peanut in the 4-to-7 age group if approved, development of other product candidates, and general working capital purposes.

The registration statement became automatically effective upon filing with the SEC. No prospectus will require approval from the French Financial Markets Authority, as the offering targets qualified investors and falls under applicable exemptions under EU Prospectus Regulation. No public offering of the ADSs will be made in Europe.

You May Also Be Interested In

• Csquare prices IPO at $21 per share, raising $1.01 billion
• Crescent Biopharma raises $143.7M in public offering on Nasdaq
• Leifras wins school club contract covering Itoshima City's junior highs